#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alternating hemiplegia of childhood Neutropenia Pericarditis Cardiac sarcoidosis Conjunctivitis allergic Colorectal adenocarcinoma Leiomyosarcoma Immune thrombocytopenia Angelman's syndrome Microscopic polyangiitis Interstitial lung disease Dementia Diffuse large B-cell lymphoma Peritoneal neoplasm Albright's disease More trials…

    Learn about Rare Diseases

    Focal segmental glomerulosclerosis – Basic Information Hairy cell leukaemia recurrent – Trials in Disease Isodicentric chromosome 15 syndrome Sjogren’s syndrome – Diagnostics Wolfram syndrome – Trials in Disease Systemic mastocytosis Wiskott-Aldrich syndrome – Diagnostics Fabry’s disease – Basic Information Splenic marginal zone lymphoma – Treatment Anaplastic thyroid cancer – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Insulin Lispro Elezanumab Bgb-A445 Ltp001 Sumatriptan Succinate Jk08 Floxuridine Mebufotenin Fondaparinux Sodium Isotretinoin 1,3-BUTYLENE GLYCOL Tropicamide Olmesartan Medoxomil Mycophenolate Sodium Tamoxifen Lutetium (177Lu) Oxodotreotide Atomoxetine Obefazimod Propylene Glycol Gs-5245 More therapies…

    Learn about Your Condition

    Metastases to lymph nodes Chronic fatigue syndrome Vascular graft thrombosis Haemorrhage intracranial Raynaud's phenomenon Adenomatous polyposis coli Dyskinesia Skin angiosarcoma Monkeypox Colour blindness Chronic sinusitis Still's disease Overweight Glomerulonephritis membranous Plasma cell myeloma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hemic and Lymphatic Diseases

  • Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Dexamethasone Ph. Eur.
    Austria Belgium Czechia Denmark France Germany +8

  • Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Vincristine
    • Doxorubicin
    • Cyclophosphamide
    Belgium France

  • Study on the Safety and Efficacy of PF-06835375 and Diphenhydramine Hydrochloride for Adults with Moderate to Severe Primary Immune Thrombocytopenia

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Pf-06835375
    • Diphenhydramine Hydrochloride
    Czechia Hungary Poland

  • Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone
    Belgium Denmark France Germany Greece Italy +4

  • Study on Ruxolitinib and Drug Combination for Critically Ill Adults with Acquired Hemophagocytic Syndrome

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Etoposide
    • Lidocaine Hydrochloride Monohydrate
    France

  • Study on the Effect of Famotidine in Reducing P-selectin Levels in Children with Sickle Cell Disease

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Famotidine
    France
Previous Page
1 … 88 89 90 91
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!